These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 22185667)
1. An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation. Adidala R; Devalapally H; Srivari C; Devarakonda R K; Akkinepally RR Drug Dev Ind Pharm; 2012 Sep; 38(9):1047-53. PubMed ID: 22185667 [TBL] [Abstract][Full Text] [Related]
2. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930 [TBL] [Abstract][Full Text] [Related]
4. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Chen L; Waxman DJ; Chen D; Kufe DW Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793 [TBL] [Abstract][Full Text] [Related]
6. N-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4-aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustard. Jiang Y; Hu L Bioorg Med Chem Lett; 2008 Jul; 18(14):4059-63. PubMed ID: 18556201 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560 [TBL] [Abstract][Full Text] [Related]
8. Self-immolative nitrogen mustard prodrugs for suicide gene therapy. Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097 [TBL] [Abstract][Full Text] [Related]
9. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy. Günther M; Waxman DJ; Wagner E; Ogris M Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614 [TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells. Roth T; Tang W; Eisenbrand G Anticancer Drug Des; 1995 Dec; 10(8):655-66. PubMed ID: 8595124 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents. Steinberg G; Borch RF J Med Chem; 2001 Jan; 44(1):69-73. PubMed ID: 11141089 [TBL] [Abstract][Full Text] [Related]
13. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182 [TBL] [Abstract][Full Text] [Related]
14. Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept. Skarbek C; Lesueur LL; Chapuis H; Deroussent A; Pioche Durieu C; Daville A; Caron J; Rivard M; Martens T; Bertrand JR; Le Cam E; Vassal G; Couvreur P; Desmaele D; Paci A J Med Chem; 2015 Jan; 58(2):705-17. PubMed ID: 25494842 [TBL] [Abstract][Full Text] [Related]
15. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation. Jain M; Kwon CH J Med Chem; 2003 Dec; 46(25):5428-36. PubMed ID: 14640551 [TBL] [Abstract][Full Text] [Related]
16. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard. Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272 [TBL] [Abstract][Full Text] [Related]
17. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Chen L; Yu LJ; Waxman DJ Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446 [TBL] [Abstract][Full Text] [Related]
18. Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate. Torgov MY; Alley SC; Cerveny CG; Farquhar D; Senter PD Bioconjug Chem; 2005; 16(3):717-21. PubMed ID: 15898742 [TBL] [Abstract][Full Text] [Related]